Impact of Human Immunodeficiency Virus Type 1 (HIV‐1) Subtype on Women Receiving Single‐Dose Nevirapine Prophylaxis to Prevent HIV‐1 Vertical Transmission (HIV Network for Prevention Trials 012 Study)

Abstract

In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (Nvp^R) in women enrolled in HIVNET 012. For 102 women (32 whose infants were HIV-1 infected by age 6–8 weeks and 70 whose infants were uninfected), HIV-1 subtypes included 50 (49%) subtype A, 35 (34%) subtype D, 4 (4%) subtype C, 12 (12%) recombinant subtype, and 1 unclassified. There was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.45–3.43). Nvp^R mutations were detected more frequently at 6–8 weeks postpartum in women with subtype D than in women with subtype A (adjusted OR, 4.94; 95% CI, 1.21–20.22). Additional studies are needed to further define the relationship between HIV-1 subtype and Nvp^R among women receiving Nvp prophylaxis